- Product Details
Keywords
- Asenapine Maleate
- Asenapine Maleate powder
- cas 85650-56-2
Quick Details
- ProName: Schizophrenia control materials Asenap...
- CasNo: 85650-56-2
- Molecular Formula: C17H16CLNOC4H4O4
- Appearance: white powder
- Application: Asenapine Maleate has been approved by...
- DeliveryTime: immediately
- PackAge: aluminum foil bag
- Port: HK, Shanghai, Shenzhen
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool and dry place
- Transportation: email: wonda-chem@outlook.com
- LimitNum: 10 Gram
Superiority
1.high quality:
quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.
2.reasonable price:
we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.
3.low moq:
no worry about the low moq, our moq is 1 gram or even lower.
4.good service.
fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.
5. fast shipping and secure courier.
we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.
Details
Schizophrenia control materials Asenapine Maleate
Specification of Asenapine Maleate:
Items | Specifications | Results |
Appearance | Off-white to white powder | Conforms |
Identification | H NMR spectrum of sample corresponds to that of standard preparation | Conforms |
The retention time of the major peak in the chromatogram of sample corresponds to that in the chromatogram of standard preparation | Conforms | |
Water | Not more than 0.5% w/w | 0.11% |
Residue on ignition | Not more than 0.5% w/w | 0.07% |
Purity by HPLC | NLT 99.0% | 99.03% |
Conclusion | The results can conforms to the above specification |
Usage of Asenapine Maleate
Asenapine Maleate has been approved by the FDA for the acute treatment of adults with schizophrenia and acute
treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults